ROVI announces the agreement with Hikma to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
ROVI REACHED 201.9 MILLION EUROS OF REVENUE IN THE FIRST POST-PANDEMIC QUARTER Operating revenue decreased by 2% to 201.6 million...
3 min
10/05/2023
ROVI COMMENCES CLINICAL DEVELOPMENT OF A NEW THREE-MONTHLY FORMULATION OF LETROZOLE (LETROZOLE LEBE) The objective of the new...
6 min
25/04/2023
  Madrid, 12 April, 2023 The Universidad Pontificia Comillas, in collaboration with Laboratorios Farmacéuticos ROVI, has created...
3 min
12/04/2023